DiaMedica, a biopharmaceutical company focused on developing novel treatments for type 1 diabetes, type 2 diabetes and other disorders, has named James Parsons as the vice president of Finance.
Subscribe to our email newsletter
Previously, Parsons was the chief financial officer for both private and public life science companies including Amorfix Life Sciences, Trillium Therapeutics and Lorus Therapeutics.
DiaMedica president and CEO Rick Pauls said that James brings to DiaMedica a wealth of expertise through his numerous years of experience as CFO with public and private biotech companies where his responsibilities included the negotiation of product licenses and strong links with the investment community.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.